Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thyroxine replacement therapy and circulating lipid concentrations

J A Franklyn1, J Daykin, J Betteridge

  • 1Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, UK.

Clinical Endocrinology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent manner.

Human reproduction (Oxford, England)·2014
Same author

Brain regional vulnerability to anaesthesia-induced neuroapoptosis shifts with age at exposure and extends into adulthood for some regions.

British journal of anaesthesia·2014
Same author

Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.

The Journal of clinical endocrinology and metabolism·2013
Same author

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Expression and function of thyroid hormone transporters in the microvillous plasma membrane of human term placental syncytiotrophoblast.

Endocrinology·2012
Same author

PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.

Endocrinology·2012
Same journal

Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH.

Clinical endocrinology·2026
Same journal

Subacute Thyroiditis in Denmark: A Nationwide Study of 1763 Cases.

Clinical endocrinology·2026
Same journal

Pubertal Dynamics of Sertoli and Leydig Cell Dysfunction in Klinefelter Syndrome.

Clinical endocrinology·2026
Same journal

Regarding Non-Classical Presentations of Rare Hereditary Hypoparathyroidism: A Case Series of CASR, GNA11, and GATA3 Mutations in Parathyroidology.

Clinical endocrinology·2026
Same journal

Dual Metabolic Burden of Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Gestational Diabetes in Pregnancy: Impact on Neonatal Anthropometry: Insights From the Born in Bradford Cohort.

Clinical endocrinology·2026
Same journal

Preoperative CALLY Index for Identifying Atypical Parathyroid Tumors.

Clinical endocrinology·2026
See all related articles

Thyroid hormone (T4) replacement therapy effectively lowers cholesterol in patients with subclinical hypothyroidism. Suppressing TSH levels below normal shows a greater impact on lipids than restoring TSH to normal ranges.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Thyroidology

Background:

  • Overt hypothyroidism is linked to hypercholesterolemia, but the lipid effects of subclinical thyroid dysfunction during T4 therapy are unclear.
  • Subtle thyroid function changes in patients on T4 replacement therapy can impact lipid profiles.
  • Understanding these effects is crucial for optimizing hypothyroidism management.

Purpose of the Study:

  • To investigate the impact of subtle thyroid status changes on circulating lipids in hypothyroid patients.
  • To evaluate the lipid-modifying effects of T4 therapy in subclinical hypothyroidism and varying TSH levels.

Main Methods:

  • A prospective study assessed short-term T4 treatment in 11 post-menopausal women with subclinical hypothyroidism.
  • A cross-sectional study compared 105 long-term T4-treated hypothyroid patients (normal or suppressed TSH) with 105 controls.

Related Experiment Videos

  • Fasting lipid profiles, including total cholesterol, LDL, HDL, and HDL subfractions, were measured.

    • Main Results:

    • Short-term T4 therapy significantly reduced total and LDL cholesterol in subclinical hypothyroidism.
    • TSH suppression below normal levels led to greater reductions in total and LDL cholesterol compared to normalizing TSH.
    • Long-term T4 therapy showed reduced cholesterol in older patients (over 55) with suppressed TSH, but not in those with normal TSH compared to controls.

    Conclusions:

    • Replacement therapy is recommended for patients with subclinical hypothyroidism based on lipid-modifying effects.
    • T4 doses that suppress TSH below normal ranges appear to have a more pronounced beneficial effect on lipid profiles.
    • These findings support careful TSH level monitoring and adjustment in T4 therapy for lipid management.